FDA Indicates Optimism Prevnar 13 Will Show Clinical Benefit In Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Advisory committee votes 14-1 in favor of effectiveness and safety in adults 50 and older.
You may also be interested in...
On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In Part 1 of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on fine-tuning the R&D organization for speed and efficiency and on whether innovation can be repeated.
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
Uncertainty about the effect of Pfizer’s vaccine in patients that have already had Merck’s Pneumovax 23 could cause problems.